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Abstract 
Introduction. Endometrium undergoes regular, cyclic tissue remodeling mostly associated to the endocrine 
system status. It is well-known fact that steroid hormones are strongly responsible for changes in endometrium. 
The precise mechanism of their action is still under investigation. The aim of the study was to evaluate the 
expression of metalloproteinases 2 and 7 (MMP-2, -7) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in 
human endometrium in relation to serum concentrations of estradiol and progesterone during different phases 
of menstrual cycle.
Material and methods. The study material consisted of 52 biopsy samples; 12 obtained in the proliferative 
phase, 11 in the secretory phase and 29 during menstruation. Expression of MMP-2, MMP-7 and TIMP-1 was 
assessed by immunohistochemistry. Serum concentrations of estradiol and progesterone at time of biopsy were 
evaluated by immunochemistry assay. Results of the study were statistically assessed by linear regression model. 
Results. Increased serum concentration of estradiol was associated with increased MMP-2 expression in prolif-
erative phase but decreased in secretory phase and during menstruation. No significant relationship was found 
between progesterone concentration and MMP-2 expression. Moreover, no difference in the expression of 
MMP-7 and TIMP-1 in the endometrium in relation to hormone levels and menstrual cycle phases were observed.
Conclusions. The results of the study indicate that estradiol influence MMP-2 expression in the endometrium 
depends on the phase of menstrual cycle. Such relationships were not found for MMP-7 and TIMP-1 and further 
tests clarifying association between estradiol and MMPs are needed. (Folia Histochemica et Cytobiologica 2018, 
Vol. 56, No. 3, 133–140)
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Introduction 
Endometrium is an inner layer of the uterus which 
consists of the simple columnar epithelium and con-
nective tissue stroma. A stroma develops and main-
tains its function under the influence of endocrine 
system, mostly ovarian hormones. In endometrium of 
women in reproductive age the functional layer and 
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the basal layer may be distinguished morphologically. 
Monthly during physiological cycle the functional 
layer undergoes proliferative and secretory changes 
preparing it for blastocyst implantation. However, it 
routinely exfoliates during menstruation; when ferti-
lization occurs this process does not take place. The 
basal layer remains intact during menstrual bleeding 
enabling regeneration of endometrium. In the prolif-
erative phase of the menstrual cycle, all the compo-
nents of the functional layer undergo proliferation, 
leading to the formation and expansion of uterine 
glands. After ovulation corpus luteum appears, re-
leasing progesterone which induces secretory changes. 
Glandular cores are expanding, becoming twisted 
and their epithelial cells release secretion containing 
significant amounts of glycogen, an important nutrient 
needed for embryo development. Steroid hormones 
like estradiol and progesterone have a strong influ-
ence on cell proliferation and their secretory function, 
whereas they are also responsible for the regulation 
of matrix metalloproteinases (MMPs) activity. The 
regulatory role of MMPs in the endometrium was 
investigated in both immunohistochemical and mo-
lecular studies [1–3]. 
MMPs are a family of proteolytic enzymes contain-
ing zinc ion in their active center. They are expressed 
in various tissues located in the extracellular matrix 
(EMC) as inactive proenzymes or remain attached to 
cell membranes [4]. Their primary role is degradation 
of EMC, facilitating cell migration during tissue re-
modeling. Moreover they affect other cell functions, 
e.g. induce release of growth factors controlling tissue 
restoration processes, and angiogenesis [5–9]. Their 
role in the menstrual cycle of endometrial changes 
in women of reproductive age as well their involve-
ment in embryo implantation has been studied [10, 
11]. Their activity influences the regeneration and 
organization of both endometrial components. While 
expression of many MMPs have been described in 
pathological states [12], significant differences in their 
expression and localization in the various phases of 
the physiological menstrual cycle are still not known. 
For instance, MMPs expression is present primarily in 
the stromal and vascular cells, but in-situ hybridization 
demonstrated that MMP-2 mRNA is also expressed 
in epithelial cells but MMP-7 mRNA and MMP-26 
mRNA only in the epithelial glandular cells [13–15]. 
Important regulators of MMPs activity are tissue 
inhibitors of metalloproteinases (TIMP-1 to TIMP-4) 
[16]. TIMP-1 is the main inhibitor of MMP-2 and 
MMP-9 [17, 18]. Although their significance for acti-
vation of proenzymes has been confirmed, studies on 
the role of TIMPs in the regulation of tissue activity 
and function are ongoing [19]. Moreover, immunohis-
tochemical analysis showed that TIMP-1 expression 
within the endometrium correlates with MMP-2 and 
MMP-7 expression [20]. 
Many studies describe the role of MMPs in the 
development of endometrial neoplasms [21], whereas, 
only a few focus on their expression in the normal 
endometrium, mostly in outer layer. It seems that 
finding of factors that influence proliferation and 
activity of epithelial cells may be useful for diagnostics 
and treatment of disorders caused by MMPs/TIMPs 
imbalance, e.g. abnormal uterine bleeding [20].
Most studies verify the effect of steroid hormones 
on MMP activity in endometrium in vitro (tissue 
explants cultures). For a more realistic assessment, 
in this investigation we evaluated MMP expression 
directly in the endometrium from particular days of 
menstrual cycle in regard to serum concentrations of 
estradiol and progesterone.
Material and methods
Patients. Fifty two premenopausal, healthy women aged 
25–40 with 25–30 days long menstrual cycles were qualified 
for the study. None of the participants was taking hormone 
treatment or hormonal contraception prior and during 
research. All participants signed informed consent prior 
the inclusion to the trial. The research was approved by the 
Bioethical Committee of the Medical University of Warsaw 
(KB/243/2012). Clinical data are presented in Table 1. 
Material sampling. Endometrial sampling was made in 
out-patient clinic with Pipelle de Cornier® (Laboratoire 
CCD, France). Indications for the biopsy were: “endome-
trial scratching” in 10 women with male factor infertility, 
cervical polyp in 13 women and 29 women voluntarily 
agreed for biopsy during menstruation. It was performed in 
12 women in the proliferative phase of the cycle (between 
day 8 and 13 of the cycle, mean age 34.5 years), in 11 in the 
secretory phase (day 18–23 of the cycle, mean age 36 years) 
and in 29 during bleeding (mean age 31.3 years). The ma-
terial was immediately placed in 10% formalin and sent to 
histopathological and immunohistochemical examination. 
Histopathological examination performed on hematoxylin 
and eosin stained paraffin sections did not show any abnor-
malities in microscopic image and was consistent with the 
phase of cycle in all cases. 
Additionally, in all women, 5 ml of venous blood sample 
was obtained on the day of biopsy; serum concentrations of 
estradiol and progesterone were determined by the electro-
chemiluminescence immunoassay (ECLIA; Elecsys, Cobas 
6000, Roche, Basel, Switzerland).
Immunohistochemistry. Immunohistochemical (IHC) re-
actions were carried out on 4 μm deparaffinized sections. 
All procedures were conducted according to running IHC 
protocols of Department of Pathology, Medical University 
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of Warsaw, (Dako AutostainerLink 48, Dako Omnis and 
Dako PT Link, Dako, Glostrup, Denmark). Direct mouse 
monoclonal antibodies against MMP-2 (clone 17B11, dilu-
tion 1:50; Novocastra, Leica Biosystems, Newcastle Upon 
Tyne, UK), MMP-7 (clone ID-2, dilution 1:75; Millipore, 
Billerica, MA, USA), and TIMP-1 (clone 6F6a, dilution 1:50; 
Novocastra) were used. For the detection of monoclonal 
antibodies, peroxidase-conjugated anti-mouse ImPress ™ 
reagent kit (Vector Laboratories, Burlingame, CA, USA) 
was used. 3,3-diaminobenzidine was used as chromogen. As 
internal control reactions with non-essential mouse IgG1 
(Sigma-Aldrich, St. Louis, MO, USA) instead of primary 
antibodies were performed.
Morphometric assessment. Expression of MMP-2, MMP-7 
and TIMP-1 was analyzed with a microscope (Nikon, Labo-
phot, Tokyo, Japan) equipped with a motorized stage and 
Image Pro Plus software (Medra Cybernetics Inc., Rockville, 
MD, USA). 10 random fields of each sample were photo-
graphed at × 10 magnification. Each image was thresholded, 
and the areas covered by MMP-2, MMP-7 and TIMP-1 
expression, as well as the average staining intensity, were 
quantified. Fields with histological artifacts or large areas of 
hemorrhage and necrosis were excluded. Total immunoreac-
tivity was approximated as the product of an area of a given 
field times expression intensity. As our goal was to analyze 
the expression in both the cells and the extracellular matrix 
(ECM was considered as an approximation of the total result, 
and displayed in arbitrary units (AU). This dimensionless 
quantity commonly serves in biological science to compare 
multiple measurements performed in similar environment 
and equipment. This modality of assessment gives opportunity 
to compare expression of proteins both inside of the cells and 
in the surrounding ECM. It is frequently used both clinically 
and in laboratory experiments [22].
Statistical analysis. In the analysis three response variables 
were considered: expression of MMP-2, MMP-7 and TIMP-1. 
A multiple linear regression using the ordinary least 
squares (OLS) estimator was used. This approach enables 
analysis of the isolated impact of the individual factors. 
Functional forms with non-transformed and logarithmically 
transformed response variables and hormone levels were 
considered. Additionally, for hormone levels polynomials 
and interactions with phase of the cycle were considered. 
The choice of the final functional form was based on 
a general-to-detail approach using the F test. For the final 
model diagnostics was performed to confirm its correctness 
(Ramsey test, Jarque-Bera test, Breusch-Pagan homoscedas-
ticity test). The variance inflation factor (VIF) measure of 
the co-linearity of the variables explained in the model was 
also performed for either non-transformed or logarithmic 
values. Isolation of the impact was crucial benefit of this 
study, making presented approach better comparing to 
using simple univariate analyzes such as Kruskall-Wallis or 
Spearman tests. All calculations were done using the STATA 
14 software (StataCorp LLC, College Station, Texas, USA). 
Unless otherwise indicated, the tests were carried out at 
a significance level of 5%.
Results
The IHC expressions of MMP-2, MMP-7 and TIMP-1 
were analyzed in cytoplasm of epithelial and stromal 
cells in proliferative, secretory and menstruation phas-
es (Fig. 1). In proliferative phase strong expression 
of MMP-2 was found in epithelial and stromal cells 
(Fig. 1A), whereas moderate expression of TIMP-1 
was observed only in epithelial cells (Fig. 1G). In 
secretory phase moderate expression of MMP-2 and 
weak expression of MMP-7 and TIMP-1 was found 
in epithelial cells (Fig. 1B, E, H). During menstrua-
tion stromal portion of endometrium was found to 
be relaxed as well strong expression of all analyzed 
markers was observed in cytoplasm of stromal cells 
(Fig. 1C, F, I). 
The results of expression of MMP-2, MMP-7 and 
TIMP-1 in endometrium are presented in Table 2. 
Table 1. Clinical data of 52 patients included in the study
Covariates Mean ± SD Range (min–max) Median 
Age [years] 33.02 ± 5.440 23–40 34
BMI [kg/m2] 24.55 ± 5.540 15.44–50.78 22.98
Length of bleeding [days] 18.12 ± 26.57 0–102 4.50
Estradiol conc. [pg/mL] 102.2 ± 84.03 22.37–450.7 79.56
Progesterone conc. [pg/mL] 4.88 ± 5.58 0.24–22.76 1.77
Estradiol/progesterone ratio 55.67 ± 74.18 5.7–367.1 23.41
Pregnancies [no.] 0.67 ± 0.76 0–2 0.50
Miscarriages [no.] 0.07 ± 0.43 0–3 0
SD — standard deviation
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There was a significant dependence between 
serum estradiol and MMP-2 expression in the endo-
metrium. It was different depending on the phase of 
the menstrual cycle. In the proliferative phase of the 
cycle, with 1% increase in serum estradiol levels, ex-
pression of MMP-2 in the endometrium also increased 
(on average by 0.11 AU). During the secretory phase 
of the cycle and during the menstruation, an increase 
in estradiol concentration of 1% was associated with 
a decrease in expression of MMP-2 (by 0.08 AU). Im-
munohistochemical expression of MMP-2 in different 
phases of the cycle is presented on Figures 1A–C. 
Linear regression results presented in Table 3 in-
dicate that MMP-2 expression is lower (by 64.6 AU) 
in the proliferative phase of the cycle compared to 
the secretory phase (p < 0.01; OLS results — t test). 
During the menstrual bleeding expression of MMP-2 
decreases with each day of bleeding (by an average of 
0.147 AU, p < 0.05; OLS results — T test). There were 
no significant differences in progesterone-dependent 
MMP-2 expression.
The expression of MMP-7 and TIMP-1 in the 
endometrium remained at a certain level and was 
not dependent on hormone levels or menstrual cycle 
Figure 1. Immunohistochemical expression of MMP-2 (A–C), MMP-7 (D–F) and TIMP-1 (G–I) in the human endometrium 
during different phases of menstrual cycle. Proliferative phase served as a reference (A, D, G), so that increased expression is 
seen in the glandular epithelium in secretory phase (B, E, I), and increased expression in stromal cells during menstruation 
(C, F, I). The immunohistochemical staining was performed as described in Methods. Total magnification 100×, space bars 
10 μm.
Table 2. Expression of metalloproteinases (MMP) 2 and 7 and tissue inhibitor of metalloproteinases 1 (TIMP-1) during 
successive phases of menstrual cycle assessed by immunohistochemistry in arbitrary units [AU]
MMP-2 MMP-7 TIMP-1
Secretory phase 141.38 ± 11.83 131.50 ± 11.53 139.38 ± 11.99
Proliferative phase 131.81 ± 10.06 133.81 ± 14.89 137.81 ± 5.51
Menstruation 141.86 ± 12.89 136.39 ± 11.49 143.47 ± 9.82
Menstrual cycle mean expression [range] 139.4 ± 12.58 
[54.64]
134.8 ± 12.26 
[61.72]
141.3 ± 9.6 
[49.97]
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phases. Their immunohistochemical expressions are 
presented on Figures 1D–F and G–I, respectively. 
Discussion 
Expression of MMPs in human endometrium is 
uneven during subsequent phases of menstrual cy-
cle and most MMPs have much higher expression 
during menstruation [23]. Up to date there are very 
few original reports on MMPs expression in physio-
logical endometrium, as most studies concentrated 
on endometrial cancer cases. Defining the role of 
MMPs in the course of endometrial transformation, 
proliferation, secretional changes, exfoliation and 
re-growth is essential to understand how they work 
in pathological conditions. 
Knowing the interplay between MMPs and sex 
hormones concentration in the tissues may enhance 
the treatment of many disorders from abnormal uter-
ine bleeding (AUB) spectrum. 
Correlation between MMP-2 expression  
and steroid hormones concentration
At physiological concentrations estradiol stimulates 
MMP-2 activity by increasing production and release 
of MMP-2 protein in a receptor-mediated process 
[24]. 17b-estradiol has been shown to stimulate the 
release of MMP-2 from smooth muscle of coronary 
arteries as well as from muscle cells of umbilical artery 
wall [25]. Similarly Huang et al. showed a positive 
correlation between serum estradiol concentration 
and serum MMP-2 concentration in the first stage of 
the menstrual cycle [26].
Our results indicate that the expression of MMP-2 
in the endometrium was seen throughout the cycle 
both in stroma and epithelial cells and was depend-
ent on serum estradiol levels. Mutual correlations 
depend on the phase of the menstrual cycle. The 
immunohistochemical studies have shown that in the 
proliferative phase of the cycle, as the estradiol level 
increased, MMP-2 immunoreactivity in the endome-
trium also increased. It was reversed in the secretory 
phase since estradiol increase was accompanied by 
a decrease in MMP-2 expression. The role of MMP-2 
in the proliferative phase of the menstrual cycle seems 
to be stimulation of endometrial cell proliferation 
and angiogenesis [27, 28]. In the secretory phase the 
increase in the synthesis and release of estradiol and 
progesterone is almost parallel [29]. This may explain 
the negative relationship between estradiol levels in 
the blood and expression of MMP-2 in the endo-
metrium. In physiological conditions progesterone 
prevents endometrial breakdown by inhibiting MMPs 
via its nuclear receptor [30]. However, it was showed 
in vitro that adding RU486, progesterone receptor 
inhibitor, to the stromal cell culture increased MMP-2 
production which was dependent on de novo protein 
synthesis since it was suppressed by cycloheximide 
[31]. In other studies, also conducted in vitro, Zhang 
et al. have demonstrated that progesterone inhibited 
MMP-2 activation [32]. In another study conducted on 
ovariectomized monkeys, Brenner et al. demonstrated 
an increase in MMP-2 expression both by IHC and 
PCR after removal of progesterone-releasing implant; 
however, in subsequent days the MMP-2 expression 
decreased despite lack of progesterone [33]. 
Increased expression of MMP-2 in the secretory 
phase may be associated with increased synthesis of 
collagens type IV, V, fibronectin, and laminin by stro-
mal cells [34]. Balance between various components of 
the extracellular matrix during endometrial changes is 
regulated by the activity of MMPs and other enzymes. 
The reduction of steroid hormone levels strongly in-
duces MMP-2 activity leading to the degradation of 
basal membranes and stromal breakdown resulting 
in the onset of menstruation [31].
Correlation between MMP-7 expression  
and steroid hormones concentration
The expression of MMP-7 was found mainly in the ep-
ithelial cells. In contrast to MMP-2, MMP-7 expres-
sion within the endometrium remained at a certain 
level and did not differ between the proliferative and 
the secretory phase, and was irrespective of estradiol 
and progesterone concentrations. MMP-7 expression 
during proliferative and secretory phases suggests 
that MMP-7 participates not only in the extracel-
lular matrix breakdown but also in the remodeling 
processes ongoing in non-menstrual endometrium, 
Table 3. Factors that significantly affect MMP-2 expression 
in endometrium (linear regression model) 
Covariates Existence MMP-2  
Coef. (SE)
Menstrual cycle:
Proliferative phase –64.554** (22.735)
Length of bleeding –0.149* (0.061)
Hormones:
Log (Estradiol) –8.083*** (2.559)
Proliferative Phase ¥ Log (Estradiol) 11.758* (4.834)
Miscarriage:
3 times miscarriages 25.175* (10.645)
Constant 179.009*** (11.525)
SE — standard error
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such as epithelial cell migration, proliferation and 
apoptosis, which are needed to regenerate the en-
dometrium after menstruation. Berton et al. showed 
that MMP-7 targeting the plasma membrane of 
epithelial cell focally promotes its activity, a mech-
anism which could be important to allow MMP-7 
action on substrates associated to the epithelial cell 
membrane, such as E-cadherin, b4-integrin, TNF-a, 
Fas, Fas ligand, heparin-binding EGF, IGF binding 
proteins and plasminogen [35]. There are limited re-
cent studies concerning correlation between MMP-7 
expression and hormone levels, nevertheless, some 
classical experiments by Osteen’s and Rudolph-Ow-
en’s groups explain these dependences well. Osteen 
et al. demonstrated that epithelial cells treated with 
estradiol (proliferative phase conditions) produced 
only MMP-7 [36]. The lack of increased expression 
of MMP-7 along with an increase in estradiol levels 
possibly indicate the inhibitory effect of other factors, 
probably such as progesterone and local inhibiting 
factors that are released directly into the stroma 
[35]. Rudolph-Owen et al. demonstrated that endo-
metrial expression of MMPs, including MMP-7 in 
endometrial proliferative phase, is similar in regular 
proliferative phase as well in ovariectomized animal 
model. In their study increased expression of MMP-
7 occurred only until 2 days after discontinuation of 
progesterone and then decreased and persisted low 
for a further 9 days despite the absence of proges-
terone [37]. 
Physiologically, the increase in MMP-7 expression 
was found only in the first days of menstruation, indi-
cating the importance of this enzyme for the normal 
process of endometrial exfoliation. Regeneration of 
the endometrium usually begins at the second day of 
the cycle, whereas bleeding disappears when the endo-
metrium reepithelization process is complete [38, 39].
Correlation between TIMP-1 expression  
and concentrations of steroid hormones
The results of our study indicate that TIMP-1 may 
be important for maintaining endometrial stability. 
TIMP-1 expression was present in the endometrium 
throughout the whole cycle at a constant level and was 
not dependent on estradiol or progesterone concen-
trations. The lack of this dependence was shown in in 
vitro studies. Lockwood et al. showed by Northern-blot 
analysis that supplementation of cell culture with both 
steroid hormones or progesterone separately did not 
affect TIMP-1 mRNA expression [40]. There is an 
evidence for changes of TIMP-1 mRNA expression 
depending on the phase of menstrual cycle. Maatta 
et al. using in-situ hybridization and Northern-blot 
techniques showed decreased expression of TIMP-1 
mRNA in the proliferative phase, while increased 
expression was found in the late secretory phase [41]. 
Our results are similar to those of Rogers at al. and 
Lockwood et al., who in in-situ hybridization studies, 
showed lack of temporal regulation of TIMP-1 mRNA 
expression during menstrual cycle [42].
In our study TIMP-1 was expressed equally 
throughout the cycle. The slight increase at menstru-
ation was not statistically significant. TIMP-1 was im-
munolocalized in the epithelial, stromal and vascular 
compartments of the endometrium. Maatta et al. using 
in-situ hybridization and Northern-blot technique 
showed decreased expression of TIMP-1 mRNA in 
the proliferative phase, while increased expression was 
found in the late secretory phase [41]. Our results are 
similar to Lockwood et al., who in in-situ hybridization 
studies, showed lack of temporal regulation of TIMP-
1 mRNA expression during menstrual cycle [40, 42].
The TIMP-1 expression in the endometrium was 
not dependent neither on estradiol nor progesterone 
concentration. The lack of hormonal dependence was 
shown in other in vitro studies [40, 43]. The results of 
our study indicate that TIMP-1 may be important for 
maintaining endometrial stability and prevent tissue 
breakdown during the menstrual cycle. 
Conclusions
The mechanism by which estradiol and progesterone 
regulate expression of MMPs and TIMPs remains 
unclear. The results of our study confirm the in-
volvement of estrogens in the regulation of MMP-2 
expression in the endometrium. However, complex 
dependence on the hormone concentration as well 
on the phase of menstrual cycle strongly suggests 
interplay with other factors. Such relations were not 
found for MMP-7 and TIMP-1 and further studies 
should be focused on their evaluation. 
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